ACADIA Pharmaceuticals Inc. vs Kimberly Clark Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Kimberly Clark Corp trades at $108.57 (market cap $36.11B). The key difference: Kimberly Clark Corp is far larger — about 7.1× ACADIA Pharmaceuticals Inc.'s market cap, and Kimberly Clark Corp pays a 4.72% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KMB | |
|---|---|---|
Market Cap | $5.07B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $134.81 |
52-Week Low | $20.06 | $93.05 |
Enterprise Value | $4.19B | $41.67B |
Dividend Yield | — | 4.72% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →